Enanta Pharmaceuticals Long Term Debt

Enanta Pharmaceuticals (ENTA) currently reports a long-term debt of $52M as of June 2026. That compares with $180M in the prior-year period — down 70.8% year over year. Use the charts on this page to explore Enanta Pharmaceuticals's long-term debt history and peer comparisons.

Enanta Pharmaceuticals's long-term debt decreased from $180M to $52M — a 70.8% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Enanta Pharmaceuticals reported $52M in long-term debt as of June 2026. That compares with $180M in the prior-year period — down 70.8% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current long-term debt of $52M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Enanta Pharmaceuticals, and consider following ENTA for alerts when major investors trade the stock.

Enanta Pharmaceuticals is classified in the Healthcare sector. On long-term debt, it currently shows $52M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing ENTA with unrelated industries.